|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 231.3 USD | -2.33% |
|
+2.75% | -10.40% |
| 05:09pm | Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease | MT |
| 12:25pm | Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating | MT |
Jan 12 (Reuters) - Biogen Inc:
* BIOGEN - TO CONTINUE TO URGE CMS TO ALIGN MEDICARE COVERAGE FOR CLASS OF AMYLOID-DIRECTED THERAPIES WITH POPULATIONS STUDIED IN RESPECTIVE CLINICAL TRIALS, FOR APPROPRIATE USE
* BIOGEN - COVERAGE WITH EVIDENCE DEVELOPMENT (CED) UNDER A RANDOMIZED CLINICAL TRIAL WILL EXCLUDE ALMOST ALL ALZHEIMER’S PATIENTS WHO MAY BENEFIT Source text for Eikon: Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| -10.40% | 34.48B | |
| +6.96% | 98.81B | |
| +7.24% | 42.32B | |
| +82.32% | 29.83B | |
| -12.23% | 15.93B | |
| +0.72% | 14.01B | |
| -12.13% | 11.52B | |
| +173.60% | 10.45B | |
| +6.82% | 9.06B | |
| -55.33% | 9B |
BIOGEN INC. 
